(Q24236743)

2

0 references

Feng Gao

3

0 references

Zengnan Mo

4

0 references

Yunfei Cao

Cochrane Database of Systematic Reviews

5

0 references

publication date

17 March 2010

0 references

published in

0 references

cites work

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

Phase II trial of sorafenib in advanced thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

Phase II trial of sorafenib in metastatic thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

A phase II study of gefitinib in patients with advanced thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

Motesanib diphosphate in progressive differentiated thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

21 January 2018

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

Differentiated carcinoma of the thyroid with extrathyroidal extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

Tumorigenesis and the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

Intussusceptive angiogenesis: its emergence, its characteristics, and its significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

A Coefficient of Agreement for Nominal Scales

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

The implications of angiogenesis for the biology and therapy of cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

What Is the Evidence That Tumors Are Angiogenesis Dependent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

Locally advanced thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

The case of the misleading funnel plot

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

Anti-angiogenic therapy: rationale, challenges and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

Treating cancer by inhibiting angiogenesis: new hopes and potential pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

The importance of preoperative laryngoscopy in patients undergoing thyroidectomy: voice, vocal cord function, and the preoperative detection of invasive thyroid malignancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

Prognostic factors in differentiated carcinoma of the thyroid gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

Investigating and Dealing with Publication and Other Biases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

External radiotherapy in thyroid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007958.PUB2

Role of surgery in treatment of advanced differentiated thyroid carcinomas

21 January 2018

1 reference

12 December 2020

Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000.

1 reference

12 December 2020

Postoperative irradiation for thyroid cancer

1 reference

12 December 2020

A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma

1 reference

12 December 2020

Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas

1 reference

12 December 2020

131-I treatment of micronodular pulmonary metastases from papillary thyroid carcinoma

1 reference

12 December 2020